Literature DB >> 29371330

Treatment of refractory thyroid cancer.

Amandine Berdelou1, Livia Lamartina2, Michele Klain3, Sophie Leboulleux1, Martin Schlumberger1.   

Abstract

Distant metastases from thyroid cancer of follicular origin are uncommon. Treatment includes levothyroxine administration, focal treatment modalities with surgery, external radiation therapy and thermal ablation, and radioiodine in patients with uptake of 131I in their metastases. Two-thirds of distant metastases become refractory to radioiodine at some point, and when there is a significant tumor burden and documented progression on imaging, a treatment with a kinase inhibitor may provide benefits.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  follicular thyroid cancer; papillary thyroid cancer; precision medicine; radioactive iodine; refractory thyroid cancer; risk stratification; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2018        PMID： 29371330     DOI： 10.1530/ERC-17-0542

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  18 in total

Review 1.  Current practice in patients with differentiated thyroid cancer.

Authors:  Martin Schlumberger; Sophie Leboulleux
Journal:  Nat Rev Endocrinol       Date:  2020-12-18       Impact factor: 43.330

2.  Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network.

Authors:  Françoise Bonichon; Thierry de Baere; Amandine Berdelou; Sophie Leboulleux; Anne-Laure Giraudet; Marie Cuinet; Delphine Drui; Renan Liberge; Antony Kelly; Florence Tenenbaum; Paul Legmann; Christine Do Cao; Laurence Leenhardt; Michel Toubeau; Yann Godbert; Jean Palussière
Journal:  Endocrine       Date:  2021-03-26       Impact factor: 3.633

3.  ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells.

Authors:  Shou-Sen Huang; Chung-Hsin Tsai; Chi-Yu Kuo; Ying-Syuan Li; Shih-Ping Cheng
Journal:  Endocrine       Date:  2022-06-27       Impact factor: 3.925

4.  Siglec-15 Silencing Inhibits Cell Proliferation and Promotes Cell Apoptosis by Inhibiting STAT1/STAT3 Signaling in Anaplastic Thyroid Carcinoma.

Authors:  Xiaofeng Hou; Chao Chen; Xiaodong He; Xiabin Lan
Journal:  Dis Markers       Date:  2022-06-20       Impact factor: 3.464

5.  Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Authors:  Valentina Maggisano; Marilena Celano; Saverio Massimo Lepore; Marialuisa Sponziello; Francesca Rosignolo; Valeria Pecce; Antonella Verrienti; Federica Baldan; Catia Mio; Lorenzo Allegri; Marianna Maranghi; Rosa Falcone; Giuseppe Damante; Diego Russo; Stefania Bulotta
Journal:  Endocrine       Date:  2019-01-19       Impact factor: 3.633

6.  Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.

Authors:  Arnaud Jannin; Livia Lamartina; Coralie Moutarde; Mehdi Djennaoui; George Lion; Benjamin Chevalier; Marie Christine Vantyghem; Frédéric Deschamps; Julien Hadoux; Eric Baudin; Martin Schlumberger; Sophie Leboulleux; Christine Do Cao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-02-12       Impact factor: 10.057

7.  The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells.

Authors:  Lorenzo Allegri; Federica Baldan; Sudeshna Roy; Jeffrey Aubé; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.996

8.  Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer.

Authors:  Mehtap Derya Aydemirli; Willem Corver; Ruben Beuk; Paul Roepman; Nienke Solleveld-Westerink; Tom van Wezel; Ellen Kapiteijn; Hans Morreau
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

Review 9.  Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.

Authors:  X Cai; R Wang; J Tan; Z Meng; N Li
Journal:  Clin Transl Oncol       Date:  2021-06-08       Impact factor: 3.405

10.  Molecular characterization of papillary thyroid carcinoma: a potential three-lncRNA prognostic signature.

Authors:  Xin You; Sheng Yang; Jing Sui; Wenjuan Wu; Tong Liu; Siyi Xu; Yanping Cheng; Xiaoling Kong; Geyu Liang; Yongzhong Yao
Journal:  Cancer Manag Res       Date:  2018-10-08       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.